MDA Versus MDMA: What Did a Direct Human Comparison Find?
MDA and MDMA are chemically related, and MDA can appear as an active MDMA metabolite. That does not make their effects identical. A randomized human crossover study directly compared them in the same participants and also tested two experimental lysine-conjugated prodrugs.
How was the study designed?
Twenty-three healthy adults—12 women and 11 men—completed five sessions in a randomized, double-blind, placebo-controlled crossover design. The conditions were placebo, 100 mg MDMA, 92 mg MDA, 172 mg lysine-MDMA, and 164 mg lysine-MDA. The active doses were chosen to be equimolar.
Researchers repeatedly measured subjective effects, blood pressure, heart rate, temperature, pupil size, endocrine responses, adverse effects, and plasma concentrations. Sessions were separated by washout periods of at least 14 days.
How did MDA differ from MDMA?
MDA produced stronger and longer-lasting “any drug effects.” Mean effect duration was approximately 6.1 hours for MDA and 4.1 hours for MDMA. Compared with MDMA, MDA also produced more subjective stimulation, fear, negative drug effects, and visual alteration.
Plasma elimination half-lives were about 8.4 hours for MDA and 7.3 hours for MDMA. The authors concluded that MDA had a less favorable therapeutic profile and a narrower apparent margin because it produced more acute and subacute adverse effects at the tested equimolar dose.
Did the prodrug strategy work?
Lysine-MDA functioned as a slow-release prodrug. Its onset and peak were delayed relative to MDA, while the overall effects were otherwise similar. The delay did not necessarily improve tolerability.
Lysine-MDMA did not work as intended. No MDMA was detected in plasma, and participants showed no corresponding subjective or autonomic response. The authors attributed this to the tertiary amine structure preventing the expected enzymatic release.
Why does this matter for toxicology?
A laboratory report may identify both MDMA and MDA. MDA may reflect metabolism, separate ingestion, or both. The study confirms that MDA itself is pharmacologically active and can produce a longer, more psychedelic-like experience. However, the controlled doses do not create a simple blood-concentration rule for casework.
The source of MDA must be evaluated using the complete analyte pattern, specimen timing, drug-product information, and analytical method. A small metabolite concentration should not automatically be interpreted as a separately consumed dose.
Important limits
The experiment involved 23 screened healthy volunteers in a calm hospital environment and used one dose level for each substance. Recreational users, psychiatric patients, repeated dosing, mixtures, and uncontrolled settings may produce different outcomes. Because lysine-MDMA was inactive, the original factorial analysis could not be completed as planned.
This is strong evidence for a direct within-person comparison, but it is not evidence that MDA or MDMA is safe outside the controlled protocol.
Scientific source
Straumann I et al. “Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants.” Neuropsychopharmacology (2026). PubMed PMID 40999236; DOI 10.1038/s41386-025-02248-3.
